BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34741547)

  • 1.
    Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
    J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of lymph node ultrasound and whole body
    Stahlie EHA; van der Hiel B; Bruining A; van de Wiel B; Schrage YM; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
    Eur J Surg Oncol; 2021 May; 47(5):1157-1162. PubMed ID: 33353826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients.
    Helvind NM; Aros Mardones CA; Hölmich LR; Hendel HW; Bidstrup PE; Sørensen JA; Chakera AH
    Eur J Surg Oncol; 2021 Dec; 47(12):3020-3027. PubMed ID: 34120809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
    Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
    Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
    Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
    Helvind NM; Weitemeyer MB; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
    Ann Surg Oncol; 2023 Apr; 30(4):2377-2388. PubMed ID: 36752970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
    Abbott RA; Acland KM; Harries M; O'Doherty M
    Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma.
    Turner RM; Dieng M; Khanna N; Nguyen M; Zeng J; Nijhuis AAG; Nieweg OE; Einstein AJ; Emmett L; Lord SJ; Menzies AM; Thompson JF; Saw RPM; Morton RL
    Ann Surg Oncol; 2021 Aug; 28(8):4561-4569. PubMed ID: 33393039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
    Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
    J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
    Toba H; Sakiyama S; Otsuka H; Kawakami Y; Takizawa H; Kenzaki K; Kondo K; Tangoku A
    Interact Cardiovasc Thorac Surg; 2012 Nov; 15(5):859-64. PubMed ID: 22914804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
    Stahlie EHA; van der Hiel B; Stokkel MPM; Schrage YM; van Houdt WJ; Wouters MW; van Akkooi ACJ
    J Surg Oncol; 2020 Dec; 122(7):1328-1336. PubMed ID: 32783266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management.
    Mena E; Taghipour M; Sheikhbahaei S; Mirpour S; Xiao J; Subramaniam RM
    Clin Nucl Med; 2016 Sep; 41(9):e403-9. PubMed ID: 27355846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
    Twycross SH; Burger H; Holness J
    S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of clinical impact of
    Liu J; Larcos G; Howle J; Veness M
    Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.
    Andersen JAS; Spatzek AD; Vilstrup MH; Grupe P; Hess S; Holdgaard PC; Bastholt L; Gerke O; Hildebrandt MG
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2342-2351. PubMed ID: 35129651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.
    Wagner JD; Schauwecker D; Davidson D; Coleman JJ; Saxman S; Hutchins G; Love C; Hayes JT
    J Clin Oncol; 1999 May; 17(5):1508-15. PubMed ID: 10334538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.